Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver FibrosisGlobeNewsWire • 08/19/25
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 08/11/25
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/05/25
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long TermSeeking Alpha • 07/31/25
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group LimitedGlobeNewsWire • 07/30/25
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025GlobeNewsWire • 07/25/25
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASHGlobeNewsWire • 07/22/25
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing RightsZacks Investment Research • 07/17/25
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)GlobeNewsWire • 07/16/25
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver FibrosisGlobeNewsWire • 06/20/25
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care ConferenceGlobeNewsWire • 06/02/25
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH CirrhosisGlobeNewsWire • 05/10/25
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/01/25
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL CongressGlobeNewsWire • 04/29/25